Home Infusion for Multiple Sclerosis: A Guide to Every Drug and Option

The landscape of multiple sclerosis treatment has shifted significantly toward home infusion. Several of the most effective MS infusion therapies — including Ocrevus (ocrelizumab), Tysabri (natalizumab), and Rituxan (rituximab) — can now be administered at home for eligible patients. Understanding which drugs qualify, what the differences are, and how to access home treatment puts patients in a stronger position to advocate for the care setting that works best for them.

The MS Infusion Landscape in 2026

Multiple sclerosis treatment has undergone a dramatic transformation over the past decade. While oral medications and injectable drugs remain important options, some of the most effective disease-modifying therapies for MS are given by intravenous infusion. For many patients, these infusions happen every few weeks to every six months — making the setting where treatment occurs a significant quality-of-life factor.

The trend toward home infusion has accelerated, driven by patient demand, insurer cost analyses, and growing evidence that home-based infusion is safe for patients who have tolerated their medications in clinical settings. The National Multiple Sclerosis Society has recognized home infusion as a viable option for many patients receiving MS therapies.

Here is how each major MS infusion drug fits into the home infusion picture.

Ocrevus (Ocrelizumab) at Home

Ocrevus is one of the most widely prescribed infusion therapies for both relapsing and primary progressive MS. It is given every six months after an initial loading dose split into two infusions two weeks apart.

Home Infusion Eligibility

Ocrevus can be given at home for patients who have tolerated at least their first full dose (and often the first two to three infusions) in a clinical setting without significant infusion reactions. The manufacturer’s prescribing information requires observation for infusion-related reactions, which a trained home infusion nurse can provide.

What Makes Ocrevus a Good Home Candidate

• The twice-yearly schedule means fewer infusions overall, but each infusion can take 2.5 to 3.5 hours — a long time to spend at a clinic
• Infusion-related reactions are most common during the first infusion and decrease with subsequent doses
• Pre-medications (methylprednisolone, acetaminophen, and an antihistamine) are given before each infusion and can be administered by the home nurse

Tysabri (Natalizumab) at Home

Tysabri is given every four weeks, making it one of the most frequent MS infusion therapies. That monthly schedule is exactly why home infusion for Tysabri can be such a game-changer.

Home Infusion Eligibility

Tysabri is part of the TOUCH (Tysabri Outreach: Unified Commitment to Health) prescribing program, which requires infusion at a registered site by trained healthcare professionals. Home infusion pharmacies can register as TOUCH sites, and many have done so. Patients must be enrolled in the TOUCH program regardless of where the infusion takes place.

Special Considerations

• The infusion itself is relatively short — typically about one hour, plus one hour of post-infusion observation
• JCV antibody testing must continue on schedule; this does not change with home infusion
• Patients with JCV antibody-positive status require more vigilant monitoring for progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection — home infusion nurses are trained to assess for early signs

Rituxan (Rituximab) at Home

Rituxan is used off-label for MS but has become a widely prescribed option, particularly for patients who need an effective B-cell depleting therapy. It is typically given every six months.

Home Infusion Eligibility

Rituxan home infusion follows a similar pattern to Ocrevus: patients who have tolerated initial infusions in a clinical setting without severe reactions can generally transition to home. Because Rituxan is often used off-label for MS, insurance approval for home infusion may require additional documentation from the prescribing neurologist.

Practical Differences From Ocrevus

• First infusions tend to take longer (4 to 6 hours) because of a slower initial rate
• Subsequent infusions may qualify for a faster 90-minute protocol in some patients
• Biosimilar versions of rituximab (such as Truxima and Ruxience) are available and may be used in home infusion depending on pharmacy and insurer

MS Drugs That Cannot Be Given at Home

Not all MS infusion therapies are appropriate for home administration. Understanding the limitations is just as important as knowing the options.

Lemtrada (Alemtuzumab)

Lemtrada requires a 5-day initial infusion course and a 3-day retreatment course, given in a certified healthcare facility. Because of the risk of serious autoimmune reactions, thyroid disorders, and immune thrombocytopenic purpura, Lemtrada is administered only through the FDA-mandated REMS program and is not available for home infusion.

Briumvi (Ublituximab)

Briumvi, a newer anti-CD20 therapy approved for relapsing MS, has a one-hour infusion time after the initial dose. While the short infusion time might seem ideal for home infusion, current guidelines and REMS requirements generally require administration in healthcare settings. This may evolve as post-marketing data accumulates.

Mitoxantrone

Rarely used now due to cardiac toxicity risks, mitoxantrone requires cardiac monitoring and is given only in clinical settings.

Insurance and Cost Considerations

Insurance coverage for home MS infusions has improved markedly. Many commercial insurers and some Medicare Advantage plans now actively prefer or even require home infusion as the default site of care for stable patients. This is driven by the significant cost difference: hospital-based outpatient infusion typically costs insurers two to five times more than home infusion for the same drug.

However, coverage is not universal. Key insurance factors include:

• Medical vs. pharmacy benefit. Infusion drugs may be covered under a plan’s medical benefit (Part B for Medicare) or pharmacy benefit (Part D). Home infusion coverage depends on which benefit applies.
• Site-of-care policies. Some insurers have formal site-of-care optimization programs that steer patients toward home infusion. While this can feel like a restriction, it often results in lower out-of-pocket costs for the patient.
• Prior authorization. Both the drug and the home infusion service typically require separate prior authorizations.

How to Advocate for Home Infusion Access

Not every neurologist proactively offers home infusion, and not every infusion center will mention it as an alternative. Patients can take these steps to explore their options:

1. Ask your neurologist whether your current MS infusion drug is eligible for home administration based on your treatment history
2. Contact your insurance company to ask specifically about home infusion coverage for your prescribed medication
3. Research home infusion pharmacies in your area that are experienced with MS therapies and, if applicable, are registered TOUCH sites for Tysabri
4. Connect with patient advocacy organizations like the National MS Society, which maintains resources on infusion setting options and insurance navigation

The movement toward home infusion for MS is not a passing trend — it reflects a broader recognition that patients managing a chronic condition deserve treatment options that fit their lives, not the other way around. For eligible patients, home infusion can transform a recurring clinical obligation into a more manageable part of living with MS.